InnoCore Pharmaceuticals
Robert Hof is an accomplished professional in the pharmaceutical and biotechnology sectors, currently serving as the CEO of InnoCore Pharmaceuticals since June 2023 and a Board Member of LIFE Cooperative since January 2024. Previously, Robert held key leadership roles including Managing Director at Symeres, Chief Operating Officer at Syncom BV, and Director of Business Development at Pepscan. Robert's career at DSM spanned over a decade, where Robert advanced from Sr Chemist to Sr Director R&D and Innovation Strategy. Educational credentials include a PhD in Bio-organic Chemistry from the University of Groningen and a compact MBA from de Baak.
This person is not in any teams
InnoCore Pharmaceuticals
InnoCore specializes in the formulation, process development, and manufacturing of long acting and minimally invasive injectable drug delivery products. InnoCore offers a unique and highly tunable polymer platform to control the delivery drug compounds, including small molecules (e.g. peptides and low solubles) and biologics (e.g. proteins and antibodies). Our proprietary polymer platform features a variety of benefits to your API's such as: - solving toxicity challenges - maintaining/increasing stability and structural integrity of sensitive compounds (e.g. by applying low temperature process conditions during manufacturing) - sustained release of of drug molecules from days up to at least 6 months - precise control over particle size (preventing absorption by macrophages and ensuring injectability) - ensuring smooth bioavailability - enabling the use of small needle sizes for patient compliance By merging developmental collaborations and licensing partnerships with our exclusive SynBiosys biodegradable polymer technologies, we generate innovative injectable and implantable drug delivery products. We invite you to navigate through our website and discover how we can enhance the performance of your device and/or drug and add value to your product pipeline.